Barclays lowered the firm’s price target on Chemours (CC) to $16 from $19 and keeps an Equal Weight rating on the shares as part of a Q1 earnings preview for the chemicals and packaging group. The firm made negative commodity revisions and is “patiently waiting” for a turn. The overhangs on cyclical names are likely not to be addressed this quarter, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CC:
- Chemours Company: Undervalued Growth Potential Driven by TSS Segment and Market Opportunities
- Chemours upgraded to Outperform from Neutral at Mizuho
- Chemours and Energy Fuels partner to expand domestic mineral supply chain
- Energy Fuels, Chemours form rare earth and critical mineral supply chain pact
- Chemours, NTT Data, Hibiya Engineering partner on Opteon 2P50 trial
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue